Aerie Pharmaceuticals (NQ: AERI )

15.56 USD +0.10 (+0.65%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2021 Add to My Watchlist

Price and Volume

Volume	437,923
Open	15.53
Bid (Size)	15.56 (2)
Ask (Size)	15.98 (3)
Prev. Close	15.46
Today's Range	15.41 - 15.76
52wk Range	9.010 - 21.30
Shares Outstanding	46,893,289
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Aerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare Conference

May 06, 2021

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...

Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

May 05, 2021

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients...

Performance

YTD	+18.60%	+18.60%
1 Month	-10.21%	-10.21%
3 Month	-25.34%	-25.34%
6 Month	+23.69%	+23.69%
1 Year	+7.24%	+7.24%

More News

Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease

April 29, 2021

Aerie Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021

April 28, 2021

Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 28, 2021

IHE's Holdings Imply 17% Gain Potential

May 25, 2021

Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain

April 19, 2021

Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference

April 07, 2021

Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma

March 30, 2021

Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase

March 11, 2021

Aerie Pharmaceuticals to Participate in the Oppenheimer 31st Annual Virtual Healthcare Conference

March 11, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.